Radiotherapy (RT) is an important component in the treatment of medulloblastoma. For children 3 years or older, the combination of maximal safe resection, craniospinal irradiation, primary site RT boost, and chemotherapy is considered standard treatment. In this issue, Kann et al1 report that about 15% of children ages 3 to 8 years with medulloblastoma did not get RT within 90 days of surgery using the National Cancer Data Base (NCDB) registry. For these patients, 5-year overall survival was worse compared with those receiving RT within 90 days of surgery (82% vs 63.4%; P < .001).
Paulino AC, Jaboin JJ. Radiotherapy Deferral in Medulloblastoma. JAMA Oncol. 2016;2(12):1582. doi:10.1001/jamaoncol.2016.2546